Triple-negative breast cancer is a heterogeneous disease and specific therapies have not
been available for a long time. Therefore, conventional chemotherapy is still considered the …

Tumour metastasis, the movement of tumour cells from a primary site to progressively
colonize distant organs, is a major contributor to the deaths of cancer patients. Therapeutic …

Summary Background Tumour-infiltrating lymphocytes (TILs) are predictive for response to
neoadjuvant chemotherapy in triple-negative breast cancer (TNBC) and HER2-positive …

Triple negative breast cancer (TNBC) constitutes the most aggressive molecular subtype
among breast tumors. Despite progress on the underlying tumor biology, clinical outcomes …

Purpose One third of patients with triple-negative breast cancer (TNBC) achieve pathologic
complete response (pCR) with standard neoadjuvant chemotherapy (NACT). CALGB 40603 …

PURPOSE CALGB 40603 (NCT00861705), a 2× 2 randomized phase II trial, demonstrated
that adding carboplatin or bevacizumab to weekly paclitaxel (wP) followed by doxorubicin …

Background Preclinical data suggest that triple-negative breast cancers are sensitive to
interstrand crosslinking agents, and that synergy may exist for the combination of a taxane …

Angiogenesis is a vital process for the growth and dissemination of solid cancers. Numerous
molecular pathways are known to drive angiogenic switch in cancer cells promoting the …

Triple-negative breast cancer (TNBC) accounts for 15% to 20% of breast cancer cases and
is characterized by the absence of estrogen, progesterone, and human epidermal growth …

Tumours require a vascular supply to grow and can achieve this via the expression of pro-
angiogenic growth factors, including members of the vascular endothelial growth factor …